hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06369805 id: 2021-00731 briefTitle: EVALUATION OF BLOOD BIOMARKER-BASED DIAGNOSTIC AID IN OUTPATIENTS SUFFERING FROM DEPRESSION overallStatus: COMPLETED date: 2021-06-02 date: 2022-11-17 date: 2022-11-17 date: 2024-04-17 date: 2024-04-17 name: Les Toises - Psychiatry and Psychotherapy Center class: OTHER briefSummary: This is an observational (non-interventional) study, carried out in an outpatient setting, which involves a blood sampling. The primary objective of this study is to confirm the association between the EDIT-B® editing signature and early unipolar or bipolar differentiation. Results of this research may provide an aid to early diagnosis and guide clinical practice towards individualized treatment. conditions: Depressive Disorder conditions: Bipolar Disorder conditions: Bipolar Depression studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 307 type: ACTUAL name: there is no intervention measure: Psychiatric symptomatology sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Les Toises - Psychiatry and Psychotherapy Center city: Lausanne zip: 1005 country: Switzerland lat: 46.516 lon: 6.63282 hasResults: False
nctId: NCT06369792 id: 2020-00266 briefTitle: PROSPECTIVE EVALUATION OF BLOOD BIOMARKERS AS AN AID TO DIAGNOSTIC AND TREATMENT IN DRUG-NAIVE PATIENTS WITH DEPRESSION overallStatus: RECRUITING date: 2020-10-20 date: 2024-12-31 date: 2024-12-31 date: 2024-04-17 date: 2024-04-17 name: Les Toises - Psychiatry and Psychotherapy Center class: OTHER briefSummary: This is an observational (non-interventional) prospective study, carried out in drug-naïve outpatients who start a treatment with escitalopram, fluoxetine, sertraline or quetiapine. Five blood samples are collected (i.e. before initiating the drug, and then after 1, 2, 4 and 8 weeks of treatment). It does not affect the choice or the treatment dose. The primary objective of this study is to measure the association between the EDIT-B® editing signature and response to pharmacological treatment in drug-naïve patients. Results of this research could provide an aid to early diagnosis, optimize pharmacological treatment and guide clinical practice towards individualized treatment. conditions: Depressive Disorder conditions: Bipolar Disorder conditions: Bipolar Depression studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: psychiatric symptomatology measure: EDIT-B profiling sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Les Toises - Psychiatry and Psychotherapy Center status: RECRUITING city: Lausanne zip: 1005 country: Switzerland name: Aurélie Reymond-Delacrétaz, PhD role: CONTACT phone: +41584580580 email: aurelie.delacretaz@lestoises.ch lat: 46.516 lon: 6.63282 hasResults: False
nctId: NCT06369779 id: OTCS 36406866 briefTitle: Clinical Evaluation of a New Flowable and a New Sculptable Universal Bulk-fill Composite for Direct Restorative Treatment overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-12 date: 2030-12 date: 2024-04-17 date: 2024-04-17 name: Ivoclar Vivadent AG class: INDUSTRY briefSummary: The overall objective of this clinical investigation is to evaluate the clinical safety and performance of the new flowable composite TM Flow and the new sculptable composite TM Fill for restoration of class I and class II cavities. The fillings are assessed according to selected FDI criteria at baseline (7-10 days after placement of filling) and after 1, 6, 12, 24, 36 and 60 months. conditions: Class I or II Cavities in Premolars or Molars studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 65 type: ESTIMATED name: TM Fill and TM Flow measure: Postoperative hypersensitivity measure: evaluation of functional (e.g. fracture of the material and retention), biological (e.g. caries at restoration margins) and aesthetic (e.g. color match) properties of the restorations sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369766 id: 2023-02144; ko23Papadopoulou4 briefTitle: REtinal Markers In Neuroinflammatory Diseases ("REMIND") overallStatus: RECRUITING date: 2024-01-31 date: 2028-12 date: 2029-02 date: 2024-04-17 date: 2024-04-17 name: University Hospital, Basel, Switzerland class: OTHER name: University of Basel briefSummary: The goal of this observational study, including patients with Multiple Sclerosis, patients with other neuroinflammatory diseases and healthy controls, is to determine the predictive value of retinal markers in predicting disease progression. Participants complete a questionnaire and undergo various non-invasive retinal routine clinical examinations. conditions: Multiple Sclerosis conditions: Neuroinflammatory Diseases studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Optical coherence tomography (OCT) name: Static retinal vessel analyzer name: Dynamic retinal vessel analyzer name: Laser speckle flowgraphy system name: Questionnaire measure: Occurence of Progression Independent of Relapse Activity (PIRA) measure: Neuroaxonal loss in the retina (as marker of neurodegeneration in the CNS) measure: Neuroinflammation in the retina measure: Fixation instability (as marker of global neuronal dysfunction in the CNS) measure: Structural changes of the retinal vessels (as marker of systemic microvascular health) measure: (For a subgroup of participants) Functional/perfusional changes of the retinal vessels measure: Relative value of retinal markers for the prediction of PIRA compared to or combined with other biomarkers of neuroaxonal damage measure: Comparison of the examined retinal markers of Multiple Sclerosis patients with Healthy Controls and with patients with other neuroinflammatory diseases of the CNS measure: The relationship between neuroaxonal loss, functional deficits and vascular changes in Multiple Sclerosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Basel, Department of Neurology status: RECRUITING city: Basel zip: 4031 country: Switzerland name: Athina Papadopoulou, PD Dr. med. role: CONTACT phone: +41 61 32 85704 email: Athina.Papadopoulou@usb.ch name: Athina Papadopoulou, PD Dr. med. role: PRINCIPAL_INVESTIGATOR lat: 47.55839 lon: 7.57327 hasResults: False
nctId: NCT06369753 id: PR(AG)459/2023B briefTitle: Visible Abdominal Distension overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-05 date: 2025-07 date: 2024-04-17 date: 2024-04-17 name: Hospital Universitari Vall d'Hebron Research Institute class: OTHER briefSummary: Background. Abdominal distention is produced by an abnormal somatic postural tone. The authors developed an original biofeedback technique. In a randomized, placebo-controlled trial the authors demonstrated the superiority of biofeedback over placebo for the treatment of abdominal distention. However, the technique is technically complex and unpractical.
Placebo: Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period. conditions: Irritable Bowel Syndrome conditions: Dyspepsia conditions: Functional Bloating studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Biofeedback name: Placebo measure: Visible abdominal distension measure: Sensation of abdominal pressure/fullness measure: Sensation of abdominal discomfort/pain measure: Follow-up after biofeedback sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitari Vall d'Hebron city: Barcelona zip: 08035 country: Spain lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06369740 id: ENZ20-2024-INDIANAPOLIS briefTitle: Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia A Monitoring overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-06-04 date: 2024-06-04 date: 2024-04-17 date: 2024-04-17 name: Enzyre B.V. class: INDUSTRY name: Indiana Hemophilia & Thrombosis Center briefSummary: This observational study consists of two parts.
Part two of the study consists of a use scenario study in which patients with hemophilia A and HCPs will evaluate two types of non-functional mock-ups of a POC in vitro medical device. The main goal of this part is to evaluate the usability of the current prototypes of the POC device. conditions: Hemophilia A studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 102 type: ESTIMATED name: Case scenarios - questionnaire name: Case scenarios - Focus groups name: Use scenarios - Usability test name: Use scenarios - interview measure: Current management of Hemophilia A coagulation lab testing measure: Potential case scenarios for a point of care in-vitro diagnostic device for hemophilia A measure: Usability issues of the current POC in-vitro diagnostic device prototypes measure: User preferences for the point of care in-vitro diagnostic device measure: Problems with current Hemophilia A coagulation monitoring measure: Potential benefits of a POC device for home use, near-patient use or in clinic use sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Indiana Hemophilia & Thrombosis Center city: Indianapolis state: Indiana zip: 46260 country: United States lat: 39.76838 lon: -86.15804 hasResults: False
nctId: NCT06369727 id: MOB015B-VI briefTitle: Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design acronym: RIPT overallStatus: COMPLETED date: 2017-10-15 date: 2018-02-15 date: 2018-02-15 date: 2024-04-17 date: 2024-04-17 name: Moberg Pharma AB class: INDUSTRY briefSummary: A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential conditions: Erythema studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE maskingDescription: NA- Safety study count: 250 type: ACTUAL name: MOB015B name: MOB015B vehicle name: Negative irritant solution of 0.9% saline measure: To determine the potential of MOB015B to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions. measure: To assess safety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: TKL Research, Inc city: Fair Lawn state: New Jersey zip: 07410 country: United States lat: 40.94038 lon: -74.13181 hasResults: False
nctId: NCT06369714 id: CHEC2023-296 briefTitle: Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. acronym: ADHD overallStatus: RECRUITING date: 2023-02-24 date: 2025-02-24 date: 2025-02-24 date: 2024-04-17 date: 2024-04-17 name: Lei Lei, MD class: OTHER briefSummary: A multi-center, randomized controlled trial is being conducted to investigate the efficacy of a novel digital therapeutics (DTx) program that utilizes a cross-training approach between neurofeedback training and executive function training for pediatric patients (aged 6-12) diagnosed with ADHD. This gamified interactive program is designed to improve attention deficits and executive function impairments in pediatric patients with ADHD. It is delivered through an engaging iPad game in a home-based treatment format. Patients will be randomly assigned to one of three groups: medication alone, digital therapeutics alone, or a combination of both interventions. Subjects will undergo 30 treatment sessions over the 8-week period, with each session lasting 30 minutes. Investigators will reassess symptoms of ADHD, executive functions, and objective measures of attention at the end of the treatment. Additionally, questionnaires will be distributed to parents to gather their insights and feedback on the treatment approach. This innovative digital therapeutics approach is expected to improve ADHD symptoms individually and enhance therapeutic outcomes when used alongside conventional drug treatment regimens. conditions: Attention Deficit Disorder With Hyperactivity conditions: Executive Function Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Concerta name: Digital therapeutics measure: Swanson, Nolan, and Pelham IV Rating Scale measure: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for ADHD measure: Questionnaire-Children with Difficulties measure: Behavior Rating Inventory of Executive Function measure: Continuous Performance Test measure: Digital Cancellation Test sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Changzheng Hospital, Naval Medical University status: RECRUITING city: Shanghai state: Shanghai zip: 200003 country: China name: Yujiao Wang, MBBS role: CONTACT phone: 15021500051 email: 2191916146@qq.com lat: 31.22222 lon: 121.45806 facility: Changhai Hospital, Naval Medical University status: RECRUITING city: Shanghai state: Shanghai zip: 200433 country: China name: Yuanhao Cai, MBBS role: CONTACT phone: 15001969690 email: 15552283399@163.com name: Yuanhao Cai, MBBS role: SUB_INVESTIGATOR name: Lei Lei, MD role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06369701 id: C.2024.019 briefTitle: Effects Compressive Tissue Flossing on Lateral Elbow Tendinopathy in US Service Members overallStatus: RECRUITING date: 2024-02-13 date: 2024-05 date: 2024-06 date: 2024-04-17 date: 2024-04-17 name: Brooke Army Medical Center class: FED briefSummary: The purpose of this research study will be to assess the effects of a compressive tissue flossing (CTF) program on the symptoms of lateral elbow tendinopathy in United States service members. Dependent variables will be the Defense and Veteran's Pain Rating Scale (DVPRS), decrease their Patient-Rated Tennis Elbow Evaluation (PRTEE) score, increase their maximal grip strength in the affected upper extremity (UE). Measurements will be taken at baseline, immediately after the first CTF intervention, and at the 1-week follow-up, for a total of 3 measurements. conditions: Lateral Elbow Tendinopathy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Within-subjects repeated measures design primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Compressive tissue floss band measure: Patient's report of pain on the Defense and Veteran's Pain Rating Scale measure: Patient-Rated Tennis Elbow Evaluation measure: Maximal grip strength in the affected upper extremity sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brooke Army Medical Center status: RECRUITING city: Fort Sam Houston state: Texas zip: 78234 country: United States name: Carly R Cooper, PhD role: CONTACT phone: 210-808-2240 email: carly.r.cooper2.mil@health.mil name: Brian T Gregg, PhD role: CONTACT phone: (210) 808-2269 email: brian.t.gregg.mil@health.mil name: John E Elam, DSc Fellow role: PRINCIPAL_INVESTIGATOR name: Carly R Cooper, PhD role: SUB_INVESTIGATOR name: Katelyn A Culley, DSc Fellow role: SUB_INVESTIGATOR name: Tara A Haugen, DSc Fellow role: SUB_INVESTIGATOR lat: 29.45746 lon: -98.4472 hasResults: False
nctId: NCT06369688 id: Baqiyatallah University briefTitle: IDEAL SKIIN CARES Bundle to Prevent Pressure Injury acronym: IdealSkinCares overallStatus: NOT_YET_RECRUITING date: 2025-10-01 date: 2026-10-01 date: 2027-10-01 date: 2024-04-17 date: 2024-04-17 name: Baqiyatallah Medical Sciences University class: OTHER name: Tehran University of Medical Sciences name: Hamadan University of Medical Science name: Tabriz University of Medical Sciences briefSummary: The study will be a multi-center, triple-blinded, cluster randomized controlled trial (c-RCT) conducted with a three-arm parallel design and a 1:1:1 allocation ratio. The experimental groups will consist of two arms: the intervention group, where patients will receive training in relevant pressure injury care bundles, and the placebo group, where patients will receive training in an irrelevant topic like respiratory care. Both intervention and placebo groups will receive specialized pressure injury prevention (PIP) care bundle from trained wound specialist nurses (WSNs). The third arm will be the control group comprising patients who do not undergo any training course and will receive only routine standard care for PIP care bundle. The aim of c-RCT will be to compare the incidence of hospital-acquired pressure injury (HAPI) in the three study groups and to provide detailed evidence on the effect of the developed pressure injury care bundle, administered by WSNs on the development of HAPI in trained hospitalized patients, as opposed to those receiving routine standard care for PIP care bundle without training. conditions: Pressure Ulcer conditions: Pressure Injury conditions: Bed Sore conditions: Pressure Sore conditions: Decubitus Sore conditions: Decubitus Ulcer conditions: Skin Ulcer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: C-RCT will be conducted with a three-arm parallel design and a 1:1:1 allocation ratio. The experimental groups will consist of two arms: the intervention group and the placebo group. The third arm will be the control group. primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: In this placebo-controlled trial, patients will be blinded to their group allocations. Additionally, WSNs, who are trained for delivering special PIP care bundles, as well as nursing staff who are responsible for measuring wounds and collecting data, and data analyst, will also be blinded. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1620 type: ESTIMATED name: IDEAL SKIIN CARES bundles name: IDEAL SKIIN CARES bundles workshop name: Respiratory care workshop measure: Incidence of hospital-acquired pressure injury (HAPI) measure: Pressure Injury Stage measure: Patient participation in care measure: Healthcare costs measure: Self-report Patient participation in care sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369675 id: MOB015B-V briefTitle: Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design acronym: CIPT overallStatus: COMPLETED date: 2017-10-19 date: 2017-11-14 date: 2017-11-14 date: 2024-04-17 date: 2024-04-17 name: Moberg Pharma AB class: INDUSTRY briefSummary: A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design To evaluate the irritation potential of MOB015B on normal skin. Single center, randomized, controlled, evaluator blinded, within-subject comparison study conditions: Erythema studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 45 type: ACTUAL name: MOB015B name: 0.2% SLS name: 0.9% Saline name: MOB015B vehicle measure: To determine the potential of MOB015B to cause skin irritation after repeated topical application to the healthy skin of humans under controlled conditions. measure: To assess safety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: TKL Research, Inc city: Fair Lawn state: New Jersey zip: 07410 country: United States lat: 40.94038 lon: -74.13181 hasResults: False
nctId: NCT06369662 id: SECI-CD155 id: SECI-IRB-IORG0006563-545 type: OTHER domain: Scientific Research Unit briefTitle: CD155 Expression in Acute Myeloid Leukemia overallStatus: ACTIVE_NOT_RECRUITING date: 2022-07-01 date: 2023-12-31 date: 2024-08-30 date: 2024-04-17 date: 2024-04-17 name: Assiut University class: OTHER briefSummary: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020.
CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival. conditions: Acute Myeloid Leukemia studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 93 type: ACTUAL name: Flow cytometric immunophenotyping name: Complete blood count name: Bone marrow aspiration name: Cytogenetic testing name: FLT3-ITD using High resolution melting curve (HRM) analysis measure: CD155 expression level in AML patients sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: South Egypt Cancer Institute, Assiut University city: Assiut zip: 71111 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06369649 id: COOLSENSE-1 briefTitle: Coolsense and Buzzy Use on Pain Score and Anxiety Level During Insulin Injection Application overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-08-31 date: 2025-12-31 date: 2024-04-17 date: 2024-04-17 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: This study aims to determine the effect of using Coolsense, which is created using the proven effect of cold application during insulin injection, and Buzzy, which is a combination of vibration and cold application, in reducing pain and anxiety in children diagnosed with Type 1 diabetes mellitus.This randomized controlled clinical study is planned to be conducted between 05.2024-12.2025 with 147 participants between the ages of 6-12. Participants will be divided into three groups according to the randomization method: buzzy group (n = 49), coolsense group (n = 49) and control group (n = 49). Participants in the Coolsense group will receive a cold application using the coolsense device for 5 seconds before the injection. Participants in the Buzzy group will be subjected to vibration and cold application 30-60 seconds before the procedure. Participants in the control group will continue the clinic's standard procedure. Changes in participants' pain score and fear level, heart rate, blood pressure, respiratory rate and oxygen saturation will be measured at three time points: immediately before and after the procedure. Data descriptive information form, application registration form, Facial Expressions Pain Scale (FPS-R) and Child Fear Scale (CFS) will be used. The collected data will be analyzed using SPSS 15 software. The main questions it aims to answer:
* Does buzzy and coolsense application have an effect the respiratory rate of children during the insülin injection? conditions: Injection Fear conditions: Injection Site Coldness conditions: Pain conditions: Type 1 Diabetes Mellitus conditions: Pediatric Disease conditions: Nurse's Role studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Single blinding (participants) will be used in the research and the researchers will not have information about the other group.